丹诺医药

Product Pipeline	Indications	Discovery-	Preclinical-
TNP-2198 PO	H. pylori Infection
	Bacterial Vaginosis
	C. difficile Infection
TNP-2092 IV	ABSSSI
	PJI (IV)
	PJI (IA)
TNP-2092 PO	Hepatic Encephalopathy
	IBS-D
	TNP-2092 TP	Diabetic Foot Infection
Bifunctional Molecule		CRAB
		Bifunctional Molecule	NASH
	Multitargeting Molecule		NTM-PD
Multitargeting Molecule			H. pylori Infection

Technology

TenNor Therapeutics has a unique multi-targeting drug conjugate technology platform, which serves as a competent source of innovative drug candidates for its development pipeline. The technology platform consists of three components: design, synthesis, and evaluation. The key know-how lies in the evaluation system, wherein a unique isogenic drug-resistant mutant panel is established to efficiently generate key data to guide through the design and optimization of the conjugated drug molecules, so as to ensure the most balanced multi-targeting activities and pharmacodynamic synergies.

Learn more

Medical Needs

Antimicrobial agents are the cornerstone of modern medicine, saving countless lives and making many common surgeries possible. However, the problem of antimicrobial resistance is becoming more and more serious and has become a major challenge to the prevention and treatment of bacterial infections. At present, some important pathogenic bacteria have developed resistance to almost all existing antibacterial drugs, rendering the clinical treatment extremely difficult.

H. pylori Infection

Medical Device Associated Bacterial Biofilm Infection

Liver Cirrhosis Hepatic Encephalopathy

Partnering

TenNor Therapeutics proactively embraces external partnering opportunities in Chinese and overseas markets.
We warmly welcome any inquiries from domestic and overseas partners who are in great strategic/product synergies with us.

Learn more